Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 294320, 9 pages
http://dx.doi.org/10.1155/2013/294320
Review Article

Interleukin-19 in Breast Cancer

1Department of Medical Research, Chi-Mei Medical Center, Tainan 710, Taiwan
2Department of Anesthesiology, Chi-Mei Medical Center, Tainan 710, Taiwan
3Department of Biotechnology, National Formosa University, Yunlin 632, Taiwan
4Department of Pathology, Chi-Mei Medical Center, Tainan 710, Taiwan
5Institute of Medical Science, College of Health Science, Chang Jung Christian University, Tainan 711, Taiwan
6Institute of Biochemistry and Molecular Biology, Medical College, National Cheng Kung University, Tainan 701, Taiwan
7Department of Anesthesiology, College of Medicine, Taipei Medical University, Taipei 110, Taiwan

Received 13 January 2013; Revised 22 March 2013; Accepted 29 March 2013

Academic Editor: Nima Rezaei

Copyright © 2013 Ying-Yin Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. DeNardo and L. M. Coussens, “Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression,” Breast Cancer Research, vol. 9, no. 4, p. 212, 2007. View at Google Scholar · View at Scopus
  2. V. S. Rao, C. E. Dyer, J. K. Jameel, P. J. Drew, and J. Greenman, “Potential prognostic and therapeutic roles for cytokines in breast cancer (Review),” Oncology Reports, vol. 15, no. 1, pp. 179–185, 2006. View at Google Scholar · View at Scopus
  3. L. S. Lindstrom, E. Karlsson, U. M. Wilking et al., “Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2601–2608, 2012. View at Google Scholar
  4. K. Yao-Lung, C. Dar-Ren, and C. Tsai-Wang, “Clinicopathological features of triple-negative breast cancer in Taiwanese women,” International Journal of Clinical Oncology, vol. 15, no. 5, pp. 500–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. B. L. Pierce, R. Ballard-Barbash, L. Bernstein et al., “Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3437–3444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Mantovani, F. Marchesi, C. Porta, A. Sica, and P. Allavena, “Inflammation and cancer: breast cancer as a prototype,” Breast, vol. 16, supplement 2, pp. 27–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Nicolini, A. Carpi, and G. Rossi, “Cytokines in breast cancer,” Cytokine & Growth Factor Reviews, vol. 17, no. 5, pp. 325–337, 2006. View at Google Scholar
  8. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Ben-Baruch, “The multifaceted roles of chemokines in malignancy,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 357–371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Boon and B. van den Eynde, “Tumour immunology,” Current Opinion in Immunology, vol. 15, no. 2, pp. 129–130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Wilson and F. Balkwill, “The role of cytokines in the epithelial cancer microenvironment,” Seminars in Cancer Biology, vol. 12, no. 2, pp. 113–120, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. C. H. Hsing, H. C. Cheng, Y. H. Hsu et al., “Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome,” Clinical Cancer Research, vol. 18, no. 3, pp. 713–725, 2012. View at Google Scholar
  14. W. E. Naugler and M. Karin, “The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer,” Trends in Molecular Medicine, vol. 14, no. 3, pp. 109–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Massague, “TGFbeta in cancer,” Cell, vol. 134, no. 2, pp. 215–230, 2008. View at Google Scholar
  16. P. Romagnani, L. Lasagni, F. Annunziato, M. Serio, and S. Romagnani, “CXC chemokines: the regulatory link between inflammation and angiogenesis,” Trends in Immunology, vol. 25, no. 4, pp. 201–209, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Chavey, F. Bibeau, S. Gourgou-Bourgade et al., “Oestrogen receptor negative breast cancers exhibit high cytokine content,” Breast Cancer Research, vol. 9, no. 1, article R15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. S. U. Woo, J. W. Bae, J. H. Yang, J. H. Kim, S. J. Nam, and Y. K. Shin, “Overexpression of interleukin-10 in sentinel lymph node with breast cancer,” Annals of Surgical Oncology, vol. 14, no. 11, pp. 3268–3273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. N. J. Sullivan, A. K. Sasser, A. E. Axel et al., “Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells,” Oncogene, vol. 28, no. 33, pp. 2940–2947, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Purohit, S. P. Newman, and M. J. Reed, “The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer,” Breast Cancer Research, vol. 4, no. 2, pp. 65–69, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. E. E. Sabbioni, H. P. Siegrist, M. Bacchi et al., “Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment,” Breast Cancer Research and Treatment, vol. 59, no. 3, pp. 279–287, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. C. H. Hsing, H. H. Li, Y. H. Hsu et al., “The distribution of interleukin-19 in healthy and neoplastic tissue,” Cytokine, vol. 44, no. 2, pp. 221–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Commins, J. W. Steinke, and L. Borish, “The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29,” Journal of Allergy and Clinical Immunology, vol. 121, no. 5, pp. 1108–1111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Gallagher, “Interleukin-19: multiple roles in immune regulation and disease,” Cytokine and Growth Factor Reviews, vol. 21, no. 5, pp. 345–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Wolk, S. Kunz, K. Asadullah, and R. Sabat, “Cutting edge: immune cells as sources and targets of the IL-10 family members?” Journal of Immunology, vol. 168, no. 11, pp. 5397–5402, 2002. View at Google Scholar · View at Scopus
  26. W. Ouyang, S. Rutz, N. K. Crellin et al., “Regulation and functions of the IL-10 family of cytokines in inflammation and disease,” Annual Review of Immunology, vol. 29, pp. 71–109, 2011. View at Google Scholar
  27. H. Fickenscher, S. Hör, H. Küpers, A. Knappe, S. Wittmann, and H. Sticht, “The interleukin-10 family of cytokines,” Trends in Immunology, vol. 23, no. 2, pp. 89–96, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Dumoutier, C. Leemans, D. Lejeune, S. V. Kotenko, and J. C. Renauld, “Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types,” Journal of Immunology, vol. 167, no. 7, pp. 3545–3549, 2001. View at Google Scholar · View at Scopus
  29. A. Zdanov, “Structural features of the interleukin-10 family of cytokines,” Current Pharmaceutical Design, vol. 10, no. 31, pp. 3873–3884, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Chang, E. Magracheva, S. Kozlov et al., “Crystal structure of interleukin-19 defines a new subfamily of helical cytokines,” Journal of Biological Chemistry, vol. 278, no. 5, pp. 3308–3313, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Conti, D. Kempuraj, S. Frydas et al., “IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26,” Immunology Letters, vol. 88, no. 3, pp. 171–174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Pestka, C. D. Krause, D. Sarkar, M. R. Walter, Y. Shi, and P. B. Fisher, “Interleukin-10 and related cytokines and receptors,” Annual Review of Immunology, vol. 22, pp. 929–979, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Langer, E. C. Cutrone, and S. Kotenko, “The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions,” Cytokine and Growth Factor Reviews, vol. 15, no. 1, pp. 33–48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. V. Kotenko, “The family of IL-10-related cytokines and their receptors: related, but to what extent?” Cytokine and Growth Factor Reviews, vol. 13, no. 3, pp. 223–240, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Gallagher, H. Dickensheets, J. Eskdale et al., “Cloning, expression and initial characterisation of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10),” Genes and Immunity, vol. 1, no. 7, pp. 442–450, 2000. View at Google Scholar · View at Scopus
  36. C. H. Hsing, M. Y. Hsieh, W. Y. Chen, E. Cheung So, B. C. Cheng, and M. S. Chang, “Induction of interleukin-19 and interleukin-22 after cardiac surgery with cardiopulmonary bypass,” Annals of Thoracic Surgery, vol. 81, no. 6, pp. 2196–2201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. C. Liao, W. G. Liang, F. W. Chen, J. H. Hsu, J. J. Yang, and M. S. Chang, “IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α,” Journal of Immunology, vol. 169, no. 8, pp. 4288–4297, 2002. View at Google Scholar · View at Scopus
  38. S. C. Liao, Y. C. Cheng, Y. C. Wang et al., “IL-19 induced Th2 cytokines and was up-regulated in asthma patients,” Journal of Immunology, vol. 173, no. 11, pp. 6712–6718, 2004. View at Google Scholar · View at Scopus
  39. S. Pletnev, E. Magracheva, S. Kozlov et al., “Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20,” Biochemistry, vol. 42, no. 43, pp. 12617–12624, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Preimel and H. Sticht, “Molecular modeling of the interleukin-19 receptor complex. Novel aspects of receptor recognition in the interleukin-10 cytokine family,” Journal of Molecular Modeling, vol. 10, no. 4, pp. 290–296, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Parrish-Novak, W. Xu, T. Brender et al., “Interleukins 19, 20, and 24 signal through two distinct receptor complexes: differences in receptor-ligand interactions mediate unique biological functions,” Journal of Biological Chemistry, vol. 277, no. 49, pp. 47517–47523, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Menon, L. Ismail, D. Ismail, M. Merialdi, S. J. Lombardi, and S. J. Fortunato, “Human fetal membrane expression of IL-19 and IL-20 and its differential effect on inflammatory cytokine production,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 19, no. 4, pp. 209–214, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. T. Azuma, Y. Matsuo, M. Kuwamura et al., “Interleukin-19 protects mice from innate-mediated colonic inflammation,” Inflammatory Bowel Diseases, vol. 16, no. 6, pp. 1017–1028, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. Cuneo, D. Herrick, and M. V. Autieri, “Il-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability,” Journal of Molecular and Cellular Cardiology, vol. 49, no. 4, pp. 647–654, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. C. H. Yeh, B. C. Cheng, C. C. Hsu et al., “Induced interleukin-19 contributes to cell-mediated immunosuppression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass,” Annals of Thoracic Surgery, vol. 92, no. 4, pp. 1252–1259, 2011. View at Google Scholar
  46. C. H. Hsing, C. J. Chiu, L. Y. Chang, C. C. Hsu, and M. S. Chang, “IL-19 is involved in the pathogenesis of endotoxic shock,” Shock, vol. 29, no. 1, pp. 7–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. C. H. Hsing, C. C. Hsu, W. Y. Chen, L. Y. Chang, J. C. Hwang, and M. S. Chang, “Expression of IL-19 correlates with Th2 cytokines in uraemic patients,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp. 2230–2238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. H. H. Li, Y. C. Lin, P. J. Chen et al., “Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis,” British Journal of Dermatology, vol. 153, no. 3, pp. 591–595, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Sakurai, T. Kuroiwa, H. Ikeuchi et al., “Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation,” Rheumatology, vol. 47, no. 6, pp. 815–820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Gabunia, S. P. Ellison, H. Singh et al., “Interleukin-19 (IL-19) induces heme oxygenase-1 (HO-1) expression and decreases reactive oxygen species in human vascular smooth muscle cells,” Journal of Biological Chemistry, vol. 287, no. 4, pp. 2477–2484, 2012. View at Google Scholar
  51. L. Huang, H. C. Cheng, R. Isom, C. S. Chen, R. A. Levine, and B. U. Pauli, “Protein kinase Cε mediates polymeric fibronectin assembly on the surface of blood-borne rat breast cancer cells to promote pulmonary metastasis,” Journal of Biological Chemistry, vol. 283, no. 12, pp. 7616–7627, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Chaudarya and R. P. Hill, “Hypoxia and metastasis in breast cancer,” Breast Disease, vol. 26, no. 1, pp. 55–64, 2006. View at Google Scholar · View at Scopus
  53. D. Generali, A. Berruti, M. P. Brizzi et al., “Hypoxia-inducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer,” Clinical Cancer Research, vol. 12, no. 15, pp. 4562–4568, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. M. Li, Y. Pan, Y. Wei et al., “Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis,” Cancer Cell, vol. 6, no. 5, pp. 459–469, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Paduch, A. Walter-Croneck, B. Zdzisińska, A. Szuster-Ciesielska, and M. Kandefer-Szerszeń, “Role of reactive oxygen species (ROS), metalloproteinase-2 (MMP-2) and interleukin-6 (IL-6) in direct interactions between tumour cell spheroids and endothelial cell monolayer,” Cell Biology International, vol. 29, no. 7, pp. 497–505, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. R. C. Johnson, D. Zhu, H. G. Augustin-Voss, and B. U. Pauli, “Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung- metastatic rat breast and prostate carcinoma cells,” Journal of Cell Biology, vol. 121, no. 6, pp. 1423–1432, 1993. View at Google Scholar · View at Scopus
  57. M. Stein, S. Keshav, N. Harris, and S. Gordon, “Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation,” Journal of Experimental Medicine, vol. 176, no. 1, pp. 287–292, 1992. View at Publisher · View at Google Scholar · View at Scopus
  58. J. E. Maglione, D. Moghanaki, L. J. T. Young et al., “Transgenic Polyoma middle-T mice model premalignant mammary disease,” Cancer Research, vol. 61, no. 22, pp. 8298–8305, 2001. View at Google Scholar · View at Scopus
  59. H. Maeda, H. Kuwahara, Y. Ichimura, M. Ohtsuki, S. Kurakata, and A. Shiraishi, “TGF-β enhances macrophage ability to produce IL-10 in normal and tumor- bearing mice,” Journal of Immunology, vol. 155, no. 10, pp. 4926–4932, 1995. View at Google Scholar · View at Scopus
  60. F. Balkwill, K. A. Charles, and A. Mantovani, “Smoldering and polarized inflammation in the initiation and promotion of malignant disease,” Cancer Cell, vol. 7, no. 3, pp. 211–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Watanabe, P. J. Jose, and S. M. Rankin, “Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages,” Journal of Immunology, vol. 168, no. 4, pp. 1911–1918, 2002. View at Google Scholar · View at Scopus
  62. S. K. Bunt, L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg, “Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression,” Cancer Research, vol. 67, no. 20, pp. 10019–10026, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Gallagher, J. Eskdale, W. Jordan et al., “Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses,” International Immunopharmacology, vol. 4, no. 5, pp. 615–626, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. J. A. Lederer, M. L. Rodrick, and J. A. Mannick, “The effects of injury on the adaptive immune response,” Shock, vol. 11, no. 3, pp. 153–159, 1999. View at Google Scholar · View at Scopus
  65. S. T. O'Sullivan, J. A. Lederer, A. F. Horgan et al., “Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection,” Annals of Surgery, vol. 222, no. 4, pp. 482–492, 1995. View at Google Scholar · View at Scopus